Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;79(7):e82.
doi: 10.1136/annrheumdis-2019-215609. Epub 2019 May 9.

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al

Merel J l'Ami  1 , Charlotte L Krieckaert  2 , Michael T Nurmohamed  2   3 , Ronald F van Vollenhoven  3 , Theo Rispens  4 , Maarten Boers  3   5 , Gerrit Jan Wolbink  2   4
Affiliations
Comment

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al

Merel J l'Ami et al. Ann Rheum Dis. 2020 Jul.
No abstract available

Keywords: DMARDs (biologic); anti-TNF; pharmacokinetics; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MJA has no conflicts of interest to report. CLK has received honoraria for lectures from Pfizer. MTN has received research funding or speaking/consultancy honoraria from AbbVie, Pfizer, Merck, Roche, BMS, UCB, Eli Lilly, Celgene and Janssen. RFvV has received research support and grants from AbbVie, Amgen, BMS, GSK, Pfizer, Roche and UCB, and honoraria for consultancy from AbbVie, Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB and Vertex. TR has received honoraria for lectures from Pfizer, AbbVie and Regeneron, and a research grant from Genmab. MB has received consultancy from Pfizer, BMS, UCB and Teva. GJW has received research funding from Pfizer and honoraria for lectures and in advisory boards of Pfizer, UCB, BMS, AbbVie, Novartis and Biogen.

Comment on